Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMI:TSE International Medical Innovations Inc. -- Ignore unavailable to you. Want to Upgrade?

To: gg cox who wrote (32)	9/16/2003 11:41:44 PM
From: gg cox	Respond to of 66

Hi gg, those stockhouse boys are doing the digging, I'll just post their work here on SI "for the record"..thanks to butch.. EResearch has just re-initiated coverage of IMI and put out the report yesterday. Buy rating, target price of $7.00 and they admit they are on the conservative side... You can find it here: eresearch.ca Interesting bits: "We rate IMI International Medical Innovations, Inc. a Speculative Buy at current price levels with a 12-month target price of $7.00. This reflects our bullish view on the Company's robust product pipeline and target markets. We believe IMI's singular vision of predictive medicine that is simple and cost effective is at the forefront of an evolutionary change in the medical community. We recommend investors buy shares at the current levels in order to take advantage of the growth that lies ahead. We rate IMI a Speculative Buy with a 12-month target price of $7.00" "IMI and its marketing and distribution partner, McNeil Consumer Healthcare Canada - a Johnson & Johnson company - will soon be launching the first commercially available non-invasive test to measure levels of skin cholesterol as a screening tool to assess a person's risk for cardiovascular disease. Not only do we believe that this will create a stir in the media, but we also believe it will provide tremendous visibility for IMI with both consumers and investors. In fact, the commercial launch of this test should be just the beginning of a string of high-potential screening tests that IMI will unveil over the next several years." On the U.S. partnership: "In next six months, IMI is likely to sign an additional partnership agreement for the commercial rights to its skin cholesterol test in the U.S. and overseas markets. The structure of such a partnership agreement would likely be consistent with the Company's current agreement with McNeil Consumer Healthcare Canada whereby IMI receives approximately a royalty of 8% to 10% on all commercial sales of the product in Canada as well as in the entire North American insurance market. Given the worldwide presence of Johnson & Johnson, there is a distinct possibility that IMI may expand its existing agreement with McNeil to include the U.S. and various overseas markets."

To: gg cox who wrote (32)	10/23/2003 12:50:26 PM
From: gg cox	Respond to of 66

IMI International Medical Innovations Inc. Rated 'Speculative Buy' With $C7 Target by Investrend Affiliate eResearch Healthcare Analysts Christopher Sassouni, DMD and Scott Davidson, CFA Thursday October 23, 9:00 am ET NEW YORK, Oct. 23, 2003 (PRIMEZONE) -- The following is an investment opinion issued by Investrend Research Syndicate: Healthcare analysts Christopher Sassouni DMD and Scott Davidson, CFA, of Investrend Research affiliate eResearch have initiated coverage on IMI International Medical Innovations Inc. (IME - News) (Toronto:IMI.TO - News) with a ``Speculative Buy'' and a one year target price of $C7.00 In the report, which is free for a limited period of time on eResearch's website eresearch.ca and at investrendresearch.com, the analysts noted that IMI ``strives to develop rapid, non-invasive tests for the early detection and monitoring of life-threatening diseases. To date, IMI has developed a product portfolio that targets the cardiovascular disease and cancer screening markets. We believe that this product portfolio is very well positioned to capitalize on the rapidly growing market for point-of-care, non-invasive disease screening tools.'' ADVERTISEMENT The analysts added ``IMI is the first company to offer a completely non-invasive skin cholesterol test. Not only has the data shown that skin cholesterol readings actually provide more clinically relevant information than most serum cholesterol tests, but because they are non-invasive, they are far more useful and cost-effective as a screening tool.'' This is the first of a series of early detection tests expected to be rolled out by IMI over the next few years. Sassouni and Davidson assigned IMI a DCF value and one year target price of $C7.00 based on projections of royalties from its suite of products and also expect that IMI will become profitable by fiscal 2004 with EPS projected at $C0.21 rising to $C0.41 in 2005. With $C8.6 million in cash and no debt, the analysts expect that IMI has over two years of cash at its current burn rate and may be able to avoid additional equity capital raisings altogether. eResearch (Independent Equity Research Corp.) is an independent equity research firm focused on under-covered, under-followed North American equities. It has based its business model on that of the bond rating agencies and receives fees from its subscribers and the companies it covers. It does not trade in the securities of the companies it covers or accept any stock related compensation for its research services. It conducts no investment banking, consulting or investor relations services for the companies it covers. eResearch's sole business is equity research. IMI has paid eResearch a fee of $45,000 to conduct continuous research on IMI for one year. eResearch is an affiliate of Investrend Research and a member of the FIRST Research Consortium listed at investrend.com , which also contains the standards and ethics agreed to by all members of the association. Anyone interested in receiving alerts regarding eResearch research should email info@investrend.com with ``IMI'' in the subject line. Contact: IMI International Medical Innovations Inc. Andrew Weir, Director, Communications (416) 222-3449 ext. 27 email: aweir@imimedical.com Web site: www.imimedical.com biz.yahoo.com